Skip to main content
Presentation
618 Secukinumab Sustains Individual Clinical Responses over Time in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 3 Trial. American College of Rheumatology (ACR) Annual Meeting, San Diego CA, Nov. 2017. Arthritis Rheumatol 2017
American College of Rheumatology (ACR) Annual Meeting (2017)
  • P Emery
  • Iain B. McInnes, University of Glasgow
  • Philip Mease, Providence St. Joseph Health
  • et.al.
Disciplines
Publication Date
November, 2017
Citation Information
P Emery, Iain B. McInnes, Philip Mease and et.al.. "618 Secukinumab Sustains Individual Clinical Responses over Time in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 3 Trial. American College of Rheumatology (ACR) Annual Meeting, San Diego CA, Nov. 2017. Arthritis Rheumatol 2017" American College of Rheumatology (ACR) Annual Meeting (2017)
Available at: http://works.bepress.com/philip-mease/167/